Arena Pharmaceuticals (NASDAQ:ARNA) is stoked over topline data from a Phase 1 clinical trial evaluating controlled-release (CR) delivery profiles of lead drug etrasimod.
Results showed that CR delivery enabled more than a
75% reduction in average heart rate effect during the 4-hour monitoring
period. Heart rate slowed by low single digits from baseline with no
titration. Over 24 hours, the etrasimod CR heart rate was reduced or
similar to etrasimod.
The company intends to rapidly develop the CR formulation and integrate it into multiple clinical programs.
Management will host a conference call today at 4:30 pm to discuss the data.
https://seekingalpha.com/news/3557468-arena-pharma-announces-encouraging-data-on-controlled-release-etrasimod
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.